Outset Medical, Inc. (OM)
| Market Cap | 84.96M |
| Revenue (ttm) | 120.07M |
| Net Income (ttm) | -87.80M |
| Shares Out | 18.15M |
| EPS (ttm) | -7.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 853,165 |
| Open | 4.740 |
| Previous Close | 4.900 |
| Day's Range | 4.530 - 5.180 |
| 52-Week Range | 4.530 - 25.350 |
| Beta | 1.97 |
| Analysts | Strong Buy |
| Price Target | 16.00 (+241.88%) |
| Earnings Date | Nov 10, 2025 |
About OM
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and Tablo... [Read more]
Financial Performance
In 2024, Outset Medical's revenue was $113.69 million, a decrease of -12.80% compared to the previous year's $130.38 million. Losses were -$127.98 million, -25.94% less than in 2023.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for OM stock is "Strong Buy." The 12-month stock price target is $16.0, which is an increase of 241.88% from the latest price.
News
Outset Medical, Gemini Space Station, CoreWeave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mostly lower this morning, with the S&P 500 futures falling around 0.2% on Tuesday.
Outset Medical, Inc. (OM) Q3 2025 Earnings Call Transcript
Outset Medical, Inc. ( OM) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants James Mazzola - Vice President of Corporate Communications & Investor Relations Leslie Trigg - Pres...
Outset Medical Reports Third-Quarter Results
SAN JOSE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialy...
New Research Demonstrates the Advantages of an Insourced Dialysis Service Line for Acute-Care Facilities Using Outset Medical's Tablo® Hemodialysis System
Data from over 1 Million Tablo Treatments Among the Findings Presented at the American Society of Nephrology's Kidney Week 2025 Data from over 1 Million Tablo Treatments Among the Findings Presented a...
Outset Medical to Present at the 2025 Stifel Healthcare Conference
SAN JOSE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexi...
Outset Medical to Report Third Quarter 2025 Financial Results on Monday, November 10, 2025
SAN JOSE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexi...
Outset Medical, Inc. (OM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Outset Medical, Inc. (NASDAQ:OM) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 7:00 AM EDT Company Participants Leslie Trigg - President, CEO & Chairman Renee Gaeta - CFO...
Northwest Kidney Centers and Outset Medical Announce Collaboration to Grow Home Hemodialysis
Collaboration to provide patients and caregivers access to innovative home dialysis with the Tablo® Hemodialysis System Collaboration to provide patients and caregivers access to innovative home dialy...
Outset Medical to Present at the 23rd Annual Morgan Stanley Global Healthcare Conference
SAN JOSE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexi...
Top 3 Health Care Stocks That Are Preparing To Pump This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Outset Medical, Inc. (OM) Q2 2025 Earnings Call Transcript
Outset Medical, Inc. (NASDAQ:OM) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants James S. Mazzola - Head of Investor Relations Leslie L.
Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization
Company raises 2025 revenue guidance to a range of $122 million to $126 million Company raises 2025 revenue guidance to a range of $122 million to $126 million
Outset Medical Names First Chief Nursing Officer
SAN JOSE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexi...
Outset Medical to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
SAN JOSE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexi...
Why Outset Medical's Rock-Bottom Valuation Masks Explosive Growth
The company's business model leverages recurring revenue streams and strong customer retention, supporting stable long-term growth. Key risks include potential regulatory changes and execution challen...
Outset Medical to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
SAN JOSE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexi...
Outset Medical Appoints Renee Gaeta as Chief Financial Officer
SAN JOSE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexi...
Outset Medical Appoints Industry Veteran Kevin O'Boyle to its Board of Directors
SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexit...
Outset Medical to Present at RBC Global Healthcare Conference
SAN JOSE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexit...
Outset Medical, Inc. (OM) Q1 2025 Earnings Call Transcript
Outset Medical, Inc. (OM) Q1 2025 Earnings Call Transcript
Outset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use Declined
SAN JOSE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialys...
Outset Medical Announces One-for-Fifteen Reverse Stock Split
SAN JOSE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the...
Outset Medical to Present at the 45th Annual TD Cowen Health Care Conference
SAN JOSE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexi...
Outset Medical, Inc. (OM) Q4 2024 Earnings Call Transcript
Outset Medical, Inc. (NASDAQ:OM) Q4 2024 Earnings Conference Call February 19, 2025 5:00 PM ET Company Participants Jim Mazzola - Head of Investor Relations Leslie Trigg - Chair and CEO Nabeel Ahmed ...
Outset Medical Reports Fourth Quarter and Full Year 2024 Financial Results
SAN JOSE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialy...